StockData
Bolt Biotherapeutics, Inc. logo

Bolt Biotherapeutics, Inc. (BOLT) stock

BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/305% above fair value
$5.65−0.15 (-2.59%)

Close on Nov 17, 2026Market cap $10.88MP/E –Yield –

Bolt Biotherapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Bolt Biotherapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$24.80M. For fiscal 2025 it was -$39.85M. The highest annual figure on record is -$39.85M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$39.85M–
FY2024Dec 31, 2024-$61.29M–
FY2023Dec 31, 2023-$69.53M–
FY2022Dec 31, 2022-$76.50M–
FY2021Dec 31, 2021-$57.07M–
FY2020Dec 31, 2020-$47.31M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$3.08M–
Q2 FY2026Jun 30, 2026-$6.54M–
Q1 FY2026Mar 31, 2026-$8.02M–
Q4 FY2025Dec 31, 2025-$7.16M–
Q3 FY2025Sep 30, 2025-$9.73M–
Q2 FY2025Jun 30, 2025-$9.60M–
Q1 FY2025Mar 31, 2025-$13.37M–
Q4 FY2024Dec 31, 2024-$14.43M–
Q3 FY2024Sep 30, 2024-$13.97M–
Q2 FY2024Jun 30, 2024-$16.14M–
Q1 FY2024Mar 31, 2024-$16.75M–
Q4 FY2023Dec 31, 2023-$14.27M–
Q3 FY2023Sep 30, 2023-$16.75M–
Q2 FY2023Jun 30, 2023-$15.11M–
Q1 FY2023Mar 31, 2023-$23.40M–
Q4 FY2022Dec 31, 2022-$17.95M–
Q3 FY2022Sep 30, 2022-$13.45M–
Q2 FY2022Jun 30, 2022-$20.79M–
Q1 FY2022Mar 31, 2022-$24.31M–
Q4 FY2021Dec 31, 2021-$17.79M–
Q3 FY2021Sep 30, 2021-$18.73M–
Q2 FY2021Jun 30, 2021-$3.99M–
Q1 FY2021Mar 31, 2021-$16.56M–
Q4 FY2020Dec 31, 2020-$12.89M–
Q3 FY2020Sep 30, 2020-$12.52M–
Q2 FY2020Jun 30, 2020-$12.27M–
Q1 FY2020Mar 31, 2020-$9.64M–

More Bolt Biotherapeutics figures

See a number that looks wrong?